EQS-News: 3M FY 23/24: BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24
Adriaan Moelker, CEO BRAIN Biotech AG, states: “Our BioScience segment made a very strong start to the business year.
- Adriaan Moelker, CEO BRAIN Biotech AG, states: “Our BioScience segment made a very strong start to the business year.
- The BRAIN Biotech Holding segment mainly includes personnel expenses and other expenses for Group administration, further development of the BRAIN Biotech Group, stock exchange listing and M&A activities.
- CFO at BRAIN Biotech AG, Michael Schneiders, takes an optimistic view on the financial year 2023/24: “We aim to continue our organic growth path from the last two years.
- The BRAIN Biotech Group now targets a revenue range of € 58 million to € 62 million for the new financial year.